Important drug interactions between HIV drugs and encorafenib and dabrafenib

17 June 2026. Related: PK and drug interactions.

Simon Collins, HIV i-Base

The June 2026 newsletter from the Liverpool Drug Interaction website includes the following new interactions between HIV drugs with encorafenib and dabrafenib. 

The traffic light coding uses red as contraindication, amber as potential caution and green for no interactions.

Encorafenib

Recommendations have been updated due to a new study showing encorafenib to be a strong inducer of CYP3A4:

↑ Green to Red: doravirine, doravirine/lamivudine/tenofovir-DF, bictegravir/emtricitabine/tenofovir alafenamide, cabotegravir (oral), cabotegravir PrEP.

↑ Yellow to Red: rilpivirine (alone and in combinations), fostemsavir.

↑ Amber to Red: lenacapavir (as ART and PrEP).

↑ Green to Amber: dolutegravir (alone and non-rilpivirine combinations), maraviroc.

Dabrafenib

The following interactions with dabrafenib have also changed, due to a downgrade from a strong to a moderate inducer:

↓ Red to Amber: doravirine, doravirine/lamivudine/tenofovir-DF, rilpivirine, rilpivirine/emtricitabine/tenofovir alafenamide, rilpivirine/emtricitabine/tenofovir-DF, dolutegravir/rilpivirine.

↓ Red to Yellow: fostemsavir.

↓ Amber to Green: dolutegravir, dolutegravir/abacavir/lamivudine, dolutegravir/lamivudine, dolutegravir/lamivudine/tenofovir-DF, raltegravir.

comment

This free monthly newsletter is available by subscribing at the following link:
https://hiv-druginteractions.us12.list-manage.com/subscribe?u=29bc14fbf19c7cb3ffd3b9f56&id=0fb0be2769

The Liverpool team has also just launched a new website on interactions with drugs used for PrEP:
https://prep-druginteractions.org

Reference

Liverpool University Drug Interaction Website Newsletter, June 2026.
https://www.hiv-druginteractions.org/site_updates